Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Form 8-K

sec.gov

8-K — Valion Bio, Inc.

Accession: 0001683168-26-008221

Filed: 2026-11-02

Period: 2026-10-27

CIK: 0001787740

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — valion_8k.htm (Primary)

EX-10.1 — SEPARATION AGREEMENT (valion_ex1001.htm)

EX-99.1 — PRESS RELEASE, DATED OCTOBER 30, 2026 (valion_ex9901.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: valion_8k.htm · Sequence: 1

Tivic Health Systems, Inc. Form 8-K

false

0001787740

0001787740

2026-10-27

2026-10-27

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities

Exchange Act of 1934

Date of Report (Date

of earliest event reported): October 27, 2026

Valion

Bio, Inc.

(Exact name of Registrant as Specified in Its

Charter)

Delaware

001-41052

81-4016391

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

1305 E. Houston Street,

Building 1, Suite 311

San Antonio, Texas

78205

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: 888

276-6888

Not applicable.

(Former name or former address, if changed since

last report.)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b)

of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value

$0.0001 per share

VBIO

The Nasdaq Stock

Market LLC

Indicate by check mark whether the registrant is an emerging growth

company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange

Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant

has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant

to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain

Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Item 5.02(b)

On October 27, 2026, Valion Bio, Inc. (the “Company”)

notified Melinda Lackey, the Company’s General Counsel and Senior Vice President of Legal Affairs, of the termination of her employment,

effective October 30, 2026.

Item 5.02(e)

On October 31, 2026, the Company entered into

a Separation Agreement and General Release (the “Separation Agreement”) with Melinda Lackey.

Under the Separation Agreement, subject to Ms.

Lackey’s compliance with its terms and the satisfaction of the conditions set forth therein, the Company agreed to pay Ms. Lackey

a gross cash severance payment of $26,750, less applicable taxes and withholdings, in a single lump-sum payment no later than 30 days

following the effective date of the Separation Agreement.

In addition, if Ms. Lackey is eligible for and

properly elects continued medical or dental coverage under COBRA, the Company agreed to pay the applicable COBRA premiums for Ms. Lackey

and her covered dependents until the earlier of November 30, 2026 or the date on which she becomes eligible for healthcare coverage under

a subsequent employer’s health plan.

The Separation Agreement also provides for a general

release of claims by Ms. Lackey in favor of the Company and certain related parties and includes customary confidentiality, non-disparagement,

cooperation, return-of-property and other continuing obligations. Ms. Lackey agreed to forfeit any unvested equity awards and may exercise

any vested stock options only in accordance with the applicable equity plan documents.

The foregoing description of the Separation Agreement does not purport

to be complete and is qualified in its entirety by reference to the full text of the Separation Agreement, which is filed as Exhibit 10.1

to this Current Report on Form 8-K and incorporated herein by reference.

2

Item 8.01 Other Events.

On October 30, 2026, Valion Bio, Inc. (the “Company”)

announced the evaluation of its lead biologic drug candidate, Entolimod, by the Armed Forces Radiobiology Research Institute in connection

with research relating to gastrointestinal acute radiation syndrome in a therapeutic efficacy study.

A copy of the Company’s press release is

attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

Number

Description

10.1

Separation Agreement and General Release, by and between Valion Bio, Inc. and Melinda Lackey.

99.1

Press Release, dated October 30, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

* Certain personal information has been omitted

from this exhibit pursuant to Item 601(a)(6) of Regulation S-K.

2

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the

undersigned hereunto duly authorized.

VALION BIO, INC.

Date:

November 2, 2026

By:

/s/ Dean Zikria

Name: Dean Zikria

Title: Interim Chief Executive Officer

3

EX-10.1 — SEPARATION AGREEMENT

EX-10.1

Filename: valion_ex1001.htm · Sequence: 2

Exhibit 10.1

Certain personal information has

been omitted from this exhibit pursuant to Item 601(a)(6) of Regulation S-K. The omitted information is indicated by “[***]”

SEPARATION AGREEMENT AND

GENERAL RELEASE

This Separation

Agreement and General Release (the “Agreement”) is entered into by and between Melinda Lackey (“Employee”), on

Employee’s behalf and on behalf of Employee’s heirs, executors, administrators, successors and assigns (collectively, “Releasor”),

and Valion Bio, Inc. (formerly known as Tivic Health Systems, Inc.) (the “Employer”). Employee and Employer are each referred

to herein as a “Party” and collectively as the “Parties.”

WHEREAS, Employee was employed

by the Employer as the General Counsel and Senior Vice President of Legal Affairs;

WHEREAS, Employee executed

an employment agreement with Employer on May 1, 2026, and any accompanying employee invention assignment, confidentiality agreement, and

arbitration agreement, attached thereto or otherwise (collectively, the “Employment Agreement”);

WHEREAS, Employee’s

employment with Employer ended on October 30, 2026 (the “Separation Date”);

WHEREAS, the

Parties desire to fully and finally resolve and settle any and all issues between them, actual or potential, through a release of all

claims against Releasees (as defined in Paragraph 4 below) and the other promises contained herein;

NOW, THEREFORE,

in consideration of the promises and mutual covenants contained herein, and for other good and valuable consideration, the receipt and

sufficiency of which are expressly acknowledged, the Parties, intending to be legally bound, agree as follows:

1.Recitals. The Parties acknowledge and agree that the Recitals set forth above are true and accurate and are incorporated

herein by this reference.

2.Separation. Employee acknowledges that after the Separation Date, Employee shall have no further job duties or responsibilities

as an employee of the Employer. Employee further understands and agrees that after the Separation Date, Employee will no longer be authorized

to incur any expenses, liabilities, or obligations on behalf of the Employer and may not, under any circumstance, act as, or represent

that Employee has the authority to act as, an agent for the Employer.

1

3. Severance.

(a)

In consideration of the promises and mutual covenants set forth herein—including, without limitation, satisfaction of the

responsibilities identified in Paragraphs 8 and 12 below, at the Employer’s sole discretion—and for other good and valuable

consideration, the receipt and sufficiency of which are expressly acknowledged, Employee will accept, on Employee’s behalf and on

behalf of Releasor, a separation payment in the total gross amount of Twenty-Six Thousand Seven Hundred Fifty Dollars and Zero Cents ($26,750.00),

minus applicable withholdings and deductions (the “Severance”). Subject to the terms of this Agreement, the Severance shall

be paid to Employee in the form of a one-time lump-sum payment, which shall be remitted to Employee, in the same manner as that by which

Employee’s compensation had been remitted to Employee, by no later than thirty (30) days after the “Effective Date”

of this Agreement, as that term is defined below, provided that Employee executes, and does not revoke, this Agreement. The monies contemplated

under this Paragraph 3(a) shall be reported to the Internal Revenue Service (and applicable state and local tax authorities) by way of

an IRS Form W-2.

(b)

In the event that Employee is eligible to elect, and properly elects, healthcare continuation coverage (medical and/or dental)

under the Employer’s group health plans pursuant to COBRA, Employer shall directly pay to the applicable insurance carrier the COBRA

premiums for Employee and Employee’s covered dependents, if any (such payments, the “COBRA Payments”), until the earlier

of November 30, 2026 or the date on which Employee becomes eligible for healthcare coverage under a subsequent employer’s health

plan (the “COBRA Period”). Upon the earlier of November 30, 2026 or the date on which Employee becomes eligible for healthcare

coverage under a subsequent employer’s health plan, Employee shall become solely responsible for the payment of any and all COBRA

premiums which Employer had been paying as described above.

(c)

Employee acknowledges and agrees that (i) the Severance and COBRA Payments described in Paragraphs 3(a) and 3(b) above constitute

adequate consideration for all of the terms of this Agreement; (ii) Employee will not be entitled to any other compensation or benefits

from the Employer, except as expressly provided for in this Agreement; and (iii) Employee specifically waives and forgoes all rights to

any compensation or benefits of any kind that are not expressly provided to Employee under this Agreement.

(d)

In addition to the payments set forth above, as applicable, Employer shall pay to Employee after the Separation Date all unpaid

wages through the Separation Date, which shall be reduced by any and all applicable taxes and withholdings (such payment, the “Required

Payment”). Employee agrees that, subject to the Employer’s obligation, if any, to provide the Severance and COBRA Payments,

once the Required Payment has been made, any wages, salary, commissions, bonuses, compensation, or other benefits, whether monetary or

otherwise, to which Employee may have been entitled, whether by operation of law, contract, policy, or otherwise, will have been paid,

or such payments are released, waived, or settled by Employee pursuant to this Agreement.

2

4. Release and Waiver of Claims.

THIS PARAGRAPH PROVIDES A COMPLETE

RELEASE AND WAIVER OF ALL EXISTING AND POTENTIAL CLAIMS EMPLOYEE MAY HAVE AGAINST EVERY PERSON AND ENTITY INCLUDED WITHIN THE DESCRIPTION

BELOW OF “RELEASEES.” BEFORE YOU SIGN THIS AGREEMENT, YOU MUST READ THIS ENTIRE PARAGRAPH 4 CAREFULLY, AND MAKE SURE THAT

YOU UNDERSTAND IT FULLY.

(a)

For valuable consideration, including the Severance and COBRA Payments, the receipt and adequacy of which are hereby acknowledged,

Releasor does hereby unconditionally and generally release and forever discharge Employer, Velocity BioWorks, Inc., and each of their

current and former partners, associates, affiliates, subsidiaries, predecessors, successors, heirs, assigns, agents, directors, officers,

employees, members, representatives, board members, investors, advisors, lawyers, insurers, and all persons acting by, through, under,

or in concert with them, or any of them (collectively, “Releasees”), of and from any and all manner of action or actions,

cause or causes of action, in law or in equity, suits, debts, liens, liability, claims, demands, damages, losses, costs, attorneys’

fees or expenses, of any nature whatsoever, known or unknown, fixed or contingent, which Releasor now has or may hereafter have against

the Releasees, or any of them, by reason of any matter, cause, or thing whatsoever arising from the beginning of time to the date on which

Employee shall have executed this Agreement (collectively, the “Claims”).

(b)

The Claims released herein include, without limiting the generality of the foregoing, any Claims in any way arising out of, based

upon, or related to Employee’s employment by Releasees, or any of them, or the termination or cessation thereof; any claim for wages,

salary, commissions, bonuses, incentive payments, profit-sharing payments, expense reimbursements, leave, vacation, severance pay or other

benefits and/or compensation of any kind; any alleged breach of any express or implied contract or agreement; any claim arising under

any employment contract or other employment arrangement, whether express or implied, written or oral; any alleged torts or other alleged

legal restrictions on any Releasee’s right to terminate Employee’s employment; any alleged violation of any federal, state

or local statute or ordinance including, without limitation, Title VII of the Civil Rights Act of 1964, the Age Discrimination in Employment

Act, the Equal Pay Act, the Family and Medical Leave Act, the Americans With Disabilities Act, the Employee Retirement Income Security

Act, the Worker Adjustment and Retraining Notification Act, the National Labor Relations Act, Texas Labor Law, and the Texas Commission

on Human Rights Act, each as amended; and any claim for tortious or harassing conduct, infliction of mental distress, interference with

contract, fraud, libel or slander. Employee further waives any right Employee may have to recover monetary damages in connection with

a claim or charge brought on Employee’s behalf by the U.S. Equal Employment Opportunity Commission (“EEOC”) or any similar

state or local agency. Notwithstanding the foregoing, this Agreement shall not operate to release any Claims which Releasor may have with

respect to (i) any vested amounts due under or with respect to any benefit plan, if any; (ii) enforcement of the Agreement; (iii) a charge

or claim with the EEOC or any other local, state, or federal regulatory or law enforcement agency; and (iv) claims that cannot be released

as a matter of law.

(c)

Employee represents and warrants that there has been no assignment or other transfer of any interest in any Claim which any Releasor

may have against the Releasees, or any of them, and Releasor agrees to indemnify and hold the Releasees, and each of them, harmless from

any liability, Claims, demands, damages, costs, expenses and attorneys’ fees incurred by the Releasees, or any of them, as the result

of any such assignment or transfer of any rights or Claims. It is the intention of the Parties that this indemnity does not require payment

as a condition precedent to recovery by the Releasees against any Releasor under this indemnity.

(d)

Releasor expressly understands and acknowledges that it is possible that unknown losses or claims exist or that present losses

may have been underestimated in amount or severity, and Releasor explicitly took that into account in assessing the consideration underlying

this Agreement, and a portion of said consideration and the mutual covenants hereunder were given in exchange for a full satisfaction

and discharge of any and all Claims.

3

5.Covenant Not to Sue. Employee represents and warrants that Releasor has not filed or commenced any complaints, claims, actions,

grievances, or proceedings of any kind (collectively for purposes of this Paragraph 5, “Actions”) against any of the Releasees

with any court or any administrative, regulatory, or other agency or body, including, without limitation, an arbitral body, in connection

with any Claims released under Paragraph 4, above. In the event such Actions have been filed, this Agreement shall render them, and hereby

renders them, irrevocably null, void, withdrawn, and dismissed with prejudice. To the fullest extent permitted by law, Employee agrees

not to commence, maintain, prosecute, or participate in any action or proceeding of any kind against the Employer or any other Releasee

with respect to any act, omission, or occurrence up to and including the date on which Employee shall have executed this Agreement. Employee

agrees that if any Releasor hereafter commences any Action arising out of, based upon, or relating to any of the Claims released in this

Agreement or in any manner asserts against the Releasees, or any of them, any of the Claims released hereunder or any claim challenging

the enforceability of any provision of this Agreement, then Releasor shall, in addition to any other damages caused to the Releasees thereby,

be required, and agrees, to repay to Employer the entirety of the Severance. Nothing herein shall prevent Employee from raising or asserting

any defense in any suit, claim, proceeding or investigation brought by any of the Releasees, and by raising or asserting any such defense,

Employee shall not become obligated to pay attorneys’ fees under this Paragraph 5. Subject to applicable law, including, without

limitation, laws promulgated by or on behalf of the Securities and Exchange Commission, in the event that any third party, including,

without limitation, a government agency, seeks to obtain any relief on behalf of any Releasor with regard to any Claim released and waived

in this Agreement, Releasor covenants not to accept or receive any monetary relief or award that may arise out of or in connection with

any such proceeding. Employee acknowledges that different or additional facts may be discovered in addition to what is now known or believed

to be true by Employee with respect to the matters released in this Agreement, and Employee agrees that this Agreement shall be and remain

in effect in all respects as a complete and final release of the matters released, notwithstanding any different or additional facts.

6.Confidentiality of Agreement. Except as may be required by law, Employee shall keep confidential and shall not disclose

to any person (other than to Employee’s immediate family, attorney and accountant, each of whom shall be directed by Employee not

to disclose such information), any and all information concerning the existence or terms of this Agreement, except in the circumstance

of (i) Employee’s truthful testimony in court or an administrative tribunal; (ii) providing information in response to a subpoena

or order issued by a court or a government agency; and/or (iii) as otherwise required by law, including, without limitation, under the

National Labor Relations Act.

7. Arbitration Relating to this Agreement. Employee agrees that any dispute or controversy between the Parties in any way arising out of, related to, or connected with this Agreement itself shall be resolved through final and binding arbitration in New York, New York, pursuant to the Employment Arbitration Rules and Procedures of JAMS, Inc. (“JAMS”), available at www.jamsadr.com. In the event of a dispute subject to this section, the parties shall be entitled to written discovery and depositions adequate to give the parties access to documents and witnesses that are essential to the dispute, subject to the discretion of the arbitrator and pursuant to the applicable JAMS rules. The arbitrator selected shall have the authority to grant either party or both all remedies otherwise available by law, including injunctions. The arbitrator shall render an award and written opinion explaining the basis for the award. The arbitral award shall be binding upon the parties. Judgment upon the award rendered by the arbitrator may be entered in any court having competent jurisdiction thereof. Both parties shall take all reasonable steps to maintain the confidentiality of the arbitration award, including executing a confidentiality stipulation in a form acceptable to Employer. The prevailing party in such arbitration, as determined by the arbitrator, and in any enforcement or other court proceedings, shall be entitled, to the extent permitted by law, to reimbursement from the other party for all of the prevailing party’s costs (including but not limited to the arbitrator’s compensation), expenses, and attorneys’ fees, in accordance with applicable law. Provided, however, Employer shall pay for all costs which are unique to the arbitration process, if required by applicable law. The Parties acknowledge that by agreeing to arbitration pursuant to this section, they are waiving their right to a judicial forum and to a trial by jury. The Parties agree that Employer is engaged in interstate commerce and that, except as provided in this Agreement, the Federal Arbitration Act (“FAA”) shall govern the interpretation and enforcement of, and all proceedings pursuant to, this Agreement.

4

8. Return of Confidential Information and Employer Property.

(a)

Employee agrees that Employee will return to the Employer all Confidential Information in Employee’s possession or otherwise

under Employee’s control, in whatever format, whether written, recorded, electronically or digitally stored and/or retrieved, no

later than two (2) days after the Separation Date, and Employee agrees not to retain any copies of any and all documents, records, or

materials of any kind, whether written or electronically created or stored, which contain, relate to, or refer to any Confidential Information.

It is understood and agreed that Employee’s above-described return and non-retention of the Employer’s Confidential Information

is a material condition of this Agreement.

(b)

Employee agrees that, no later than two (2) days after the Separation Date, Employee will return to the Employer any and all Employer

property and equipment of any kind, including, but not limited to, access passwords relating to work Employee performed for Employer,

keys, mobile communication devices, computer equipment, files, documents, and the like (“Employer Property”).

(c)

Notwithstanding the foregoing, Employer has agreed to permit Employee to maintain possession of Employee’s Employer-provided

laptop. No later than five (5) days after November 30, 2026, Employee shall provide written confirmation that she has wiped all Employer

Confidential Information, Employer software, and Employer data off of this laptop.

9. Non-Admission; Non-Disparagement.

(a)

Neither this Agreement, nor the Severance or COBRA Payments, is intended to be, shall be construed as, or is, an admission or concession

by any of the Releasees of any wrongdoing, error, liability, or actionable acts or omissions, and the Releasees expressly deny that any

of them has engaged in any wrongdoing, error, or actionable acts or omissions.

(b)

Employee, as and on behalf of Releasor, hereby represents and agrees that Releasor shall not directly or indirectly (i) make any

written or oral statements, suggestions or representations that the Employer or any Releasee has made or implied any admission or concession

contemplated in Paragraph 9(a), above; and/or (ii) except as may be required by law, make any oral or written defaming, disparaging, negative,

or knowingly or maliciously false statements, suggestions, or representations of or concerning the Employer or any Releasee. For the avoidance

of doubt, this includes, without limitation, statements, suggestions, or representations memorialized in any medium whatsoever, whether

electronic or otherwise, including, without limitation, e-mail and social media platforms of any kind. Employee acknowledges and agrees

that violating this non-disparagement clause would constitute a material breach of this Agreement.

10.Surviving Terms of Employment Agreement. Employee acknowledges that certain terms contained in the Employment Agreement

will survive the termination of her employment with Employer. Employee understands and agrees that she will continue to be subject to,

and abide by, such terms after the Separation Date. To the extent there is a conflict between any term or provision contained in this

Agreement and the Employment Agreement, the term or provision most favorable to the Employer shall apply.

11.Equity Grants. Employee acknowledges and agrees that by virtue of this separation, Employee is forfeiting any unvested equity,

if any, pursuant to the applicable plan documents. Additionally, Employee may exercise any vested options consistent with applicable plan

documents only.

5

12.Future Cooperation.

(a)

Employee agrees that after the Separation Date, Employee shall cooperate with, and shall be available to, the Employer to assist

in any matter, including, without limitation, transitioning her duties and providing information regarding relevant operations, processes,

materials, passwords, insights, projects on which she was working prior to the Separation Date, access to files, and/or the location of

relevant information, and assisting government agency investigations and actual or potential court litigation or arbitration in connection

with which Employee may have knowledge. If Employee receives a subpoena or process from any person or entity (including, but not limited

to, any governmental agency) which would or may require Employee to disclose documents or information or provide testimony (in a deposition,

court proceeding, or otherwise) regarding, in whole or in part, any of the Releasees or any proprietary or confidential information, Employee

shall: (i) notify the Employer of the subpoena or other process within two (2) business days of receiving it (or a shorter period such

that not less than one (1) business day shall remain between such notification and any deadline for response thereto); and (ii) to the

maximum extent permissible under applicable law, not make any disclosure until the appropriate Releasees have had a reasonable opportunity

to contest the right of the requesting person or entity to such disclosure, limit the scope or nature of such disclosure, and/or seek

to participate in the proceeding or matter in which the disclosure is sought. Employee shall further cooperate with Employer in responding

to any such subpoena or process.

(b)

In addition to the foregoing, no later than two (2) days following the Separation Date, Employee shall (i) transfer administrative

rights and passwords for the systems Employee administered during her employment, including, without limitation, Paylocity, Empower, Beneflex,

DocuSign, ContractSafe and ShareFile; and (ii) provide a short written list of open legal matters and upcoming deadlines, including, without

limitation, the following:

·

the Bexar County lawsuit (Snell)

·

the CG Capital / Rich matter

·

patent counsel matters (Dentons, Launchpad, Snell)

·

the Handley proxy item, the Snell-to-Venable transition and the AFRRI agreement

·

pending 8-Ks, minutes and consents

13.Notices. Any notices or transmissions to be given hereunder by either party to the other may be effected by (a) personal

delivery in writing; (b) nationally recognized overnight delivery service; or (c) electronic mail. Notices shall be addressed to the parties

at the following addresses:

(a) If to the Employer, to:

Dean Zikria

Interim CEO

Valion Bio, Inc.

1305 E. Houston Street, Building 1, Suite 311

San Antonio, TX 78205

dean.zikria@valionbio.com

With a copy to:

William Haddad, Esq.

Venable LLP

151 W. 42nd Street, 49th Floor

New York, New York 10036

WNHaddad@Venable.com

(b) If to Employee, to:

Melinda Lackey

[***]

Either Party may change its above-noted

contact information by written notice in accordance with this Paragraph 13. Notice delivered personally will be deemed communicated as

of actual receipt, and notices sent by overnight delivery service will be deemed communicated as of the business day after sending.

6

14.Entire Agreement, Amendment, and Choice of Law. This Agreement, together with the Employment Agreement, constitutes the

sole and complete understanding and agreement between the Parties concerning the subject matter hereof. This Agreement supersedes any

previous agreements and/or understandings, whether formal or informal, and whether written or oral, between the Parties or between Employee

and the Employer regarding the subject matter hereof, except the Employment Agreement, and except as otherwise provided herein. This Agreement

may not be amended except in a writing signed by both Parties. Except as otherwise provided under the FAA or other applicable law, this

Agreement shall be governed by and construed in accordance with the laws of the State of Texas, without regard to its conflicts of laws

provisions.

15.Successors. For the avoidance of doubt, and without limiting any other provision of this Agreement, the rights, remedies,

and protections afforded to the Employer hereunder, including the rights, remedies, and protections set forth in Paragraph 4 herein, shall

inure to the benefit of the Employer’s current and former parents, subsidiaries, representatives, successors, and administrators.

16.Severability. If any provision of this Agreement is declared or determined by any court to be illegal or invalid, that part

shall be modified or excluded from this Agreement only to the extent required by law, but the validity of the remaining parts, terms,

or provisions shall not be affected and shall continue in full force and effect.

17.Counterparts. This Agreement may be executed in one or more counterparts. Each executed counterpart shall be considered

an original, all of which together shall constitute one instrument binding on the Parties. Consistent with the provisions of Paragraph

13 hereof, the Parties agree that email executed copies of this Agreement shall be deemed effective and enforceable as originals.

18. Employee Acknowledgments.

(a)

The release language contained in this Agreement constitutes, among other things, a waiver of all rights and claims Employee may

have under the Age Discrimination in Employment Act of 1967, as amended (29 U.S.C. § 621, et seq.) (the “ADEA”).

(b)

Employee has twenty-one (21) days from the date Employee is presented with a copy of this Agreement to consider whether to sign

this Agreement. Employee may unilaterally waive this twenty-one (21) day period at Employee’s election, but in no instance may

Employee sign this Agreement before the Separation Date, or it will not be valid. Employee’s signature on this Agreement constitutes

an express waiver of the twenty-one (21) day period if affixed prior to the expiration of that period. The Parties expressly agree that

any revisions or modifications to this Agreement, whether material or immaterial, will not and did not restart this twenty-one (21) day

review period. Employee further acknowledges that the period of time Employee had to consider Employee’s rights and obligations

under this Agreement was reasonable.

7

(c)

Employee may revoke Employee’s release of claims under the ADEA at any time within seven (7) days of Employee’s execution

of this Agreement. Employee’s release of claims under the ADEA shall not become effective or enforceable until this seven (7) day

revocation period has expired without Employee having exercised Employee’s right to revoke Employee’s release of claims under

the ADEA. Any such revocation by Employee must be made in a letter signed by Employee and received by Dean Zikria, with a copy to William

Haddad, at the address set forth in Paragraph 13 by no later than the eighth (8th) day following Employee’s execution of this Agreement.

If Employee does not exercise Employee’s right to revoke Employee’s release of claims under the ADEA during the seven (7)

day revocation period, this entire Agreement will take effect as of the eighth (8th) day following Employee’s execution

of this Agreement. On the other hand, if Employee duly revokes Employee’s release of claims under the ADEA during the seven (7)

day revocation period, this entire Agreement will still take effect as of the eighth (8th) day following Employee’s execution

hereof, except for Employee’s release of claims under the ADEA, and in such case, Employee shall only be entitled to twenty percent

(20%) of the Severance. In either of the foregoing instances, the eighth (8th) day following Employee’s execution of this Agreement

shall be the Agreement’s “Effective Date.”

(d)

Regardless of whether Employee revokes Employee’s release of claims under the ADEA during the seven (7) day revocation period,

under no circumstance shall the Employer be obligated to remit any portion of the Severance or COBRA Payments, nor is Employer required

to fulfill any of its obligations under this Agreement, until (i) the Effective Date of the Agreement (as defined herein) has passed;

and (ii) Employee has returned all Confidential Information and all Employer Property.

(e)

Employee has carefully read and understands all of the terms of this Agreement and agrees and acknowledges that such terms are

fair and reasonable, and are not the result of any fraud, duress, coercion, pressure, or undue influence exercised by or on behalf of

any of the Releasees. Employee has agreed to, and has entered into, this Agreement and all of the terms hereof, knowingly, freely, and

voluntarily. In executing this Agreement, Employee is not relying on, and has not relied on, any representation or statement made by any

of the Releasees or their representatives or attorneys with regard to the subject matter, basis, or effect of the Agreement, other than

as explicitly set forth herein.

(f)

Employee has been, and is hereby, advised by the Employer to consult with an attorney before executing this Agreement.

(g)

Employee is not suffering from any disability or impairment that would render Employee unable to read, consider and/or understand

this Agreement.

8

IN WITNESS WHEREOF, the Parties

hereto have executed this Separation Agreement and General Release.

Melinda Lackey

Valion Bio, Inc.

Print: Melinda Lackey

Print: Lisa Wolf

Date: 10/31/2026

Title: COO/CFO

Sign: /s/ Melinda Lackey

Date: 10/31/2026

Sign: /s/ Lisa Wolf

9

EX-99.1 — PRESS RELEASE, DATED OCTOBER 30, 2026

EX-99.1

Filename: valion_ex9901.htm · Sequence: 3

Exhibit 99.1

Valion Bio Advancing Entolimod into

U.S. Government-Funded Therapeutic Efficacy Study Following Positive Safety Results

NIAID-RNCP elects to evaluate the efficacy

of Entolimod on gastrointestinal acute radiation syndrome (“GI-ARS”), after the announcement of positive safety findings

Fully funded study will evaluate Entolimod’s

potential to improve survival rates and gastrointestinal (“GI”) tissue recovery following radiation exposure

Top-line results anticipated in early December,

providing the next key development milestone for Valion Bio’s lead biologic drug candidate and, if positive, will further support

Entolimod’s potential role in government preparedness for radiological and nuclear mass-casualty scenarios

SAN ANTONIO, TX / October 30, 2026 / ACCESS

Newswire -- Valion Bio, Inc. (NASDAQ: VBIO) (“Valion” or the “Company”), a clinical-stage biopharmaceutical company

developing biologics that activate innate immune pathways for cytoprotection and immune modulation, today announced that the Armed Forces

Radiobiology Research Institute (“AFRRI”) will be evaluating the therapeutic efficacy of Entolimod. This phase will evaluate

whether treatment administered after radiation exposure improves survival in a model designed to assess gastrointestinal acute radiation

syndrome (“GI-ARS”).

The therapeutic study is fully funded by the National

Institute of Allergy and Infectious Diseases (“NIAID”)/Radiation and Nuclear Countermeasures Program (“RNCP”)

under an Interagency Agreement with the Uniformed Services University (“USU”)/AFRRI. Top-line results are anticipated in early

December.

The decision to advance the program to the therapeutic

phase comes just days after Valion announced positive safety results. Achieving this milestone uniquely positions Valion Bio, potentially

further strengthening its competitive position, commercial opportunities, and fundamental outlook.

“NIAID’s decision to move into therapeutic

efficacy testing at AFRRI gives Entolimod a clear next milestone following the positive safety findings,” said Dean Zikria, Interim

Chief Executive Officer of Valion Bio. “The central question is now whether treatment after radiation exposure can improve survival

in a model designed to isolate gastrointestinal injury. This fully funded study provides an opportunity to evaluate that potential while

preserving Valion’s capital and generating critical efficacy data to guide Entolimod towards its next stage of development.”

Evaluating Entolimod’s Potential to Improve

Survival Following Radiation Exposure

Entolimod is being developed as a potential medical

countermeasure for both the hematopoietic (or bone marrow) and gastrointestinal (“GI”) forms of acute radiation syndrome (“ARS”).

By shielding roughly 2.5% of the animals’ bone marrow, the upcoming study’s partial-body irradiation model will enable researchers to

differentiate between effects linked to the mitigation of gastrointestinal injury and those associated with recovery.

Mice will receive a single administration of either

Entolimod or saline control 24 hours after radiation exposure and then will be monitored for 30 days. The primary endpoint is survival,

with outcomes to be compared between the treatment and control groups.

“GI-ARS remains a critical challenge in

the development of medical countermeasures,” added Mr. Zikria. “Demonstrating a survival benefit in this model would underscore

a novel and clinically significant milestone for Entolimod and further strengthen its potential role as a medical countermeasure for radiation

emergencies. We would like to thank AFRRI and NIAID for their continued support and look forward to the results from this key study.”

1

About Valion Bio, Inc.

Valion Bio, Inc. (NASDAQ:VBIO) is developing biologics

that activate innate immune pathways for cytoprotection and modulate immune responses in conditions driven by radiation, disease and immune

dysregulation.

The Company’s lead candidate, Entolimod,

is being developed as a potential medical countermeasure for Acute Radiation Syndrome (“ARS”) and has been evaluated in animal

models under the U.S. Food and Drug Administration’s (“FDA”) Animal Rule, which allows the Agency to approve new drugs

and biological products based on animal efficacy studies when human clinical trials are not ethical or feasible, such as in the case of

acute radiation exposure. Entolimod is a novel Toll-like Receptor 5 agonist designed to activate NF-κB signaling pathways associated

with cellular protection, tissue recovery and immune response. The product candidate has received Fast Track and Orphan Drug designations

from the FDA. Valion holds an exclusive, worldwide license from Statera Biopharma to develop and commercialize Entolimod for ARS, radiation-induced

neutropenia, and other indications.

Valion is also advancing Entolasta, a next-generation

TLR5 agonist designed for potential use in broader therapeutic applications, including oncology supportive care. The Company’s pipeline

includes potential programs in neutropenia and immune dysfunction.

Valion’s wholly owned subsidiary, Velocity

Bioworks, is a biologics contract development and manufacturing organization providing development and manufacturing services to Valion

to support its internal pipeline, with the objective of increasing manufacturing control, reducing costs, accelerating development timelines

and strengthening domestic supply-chain security.

For more information, visit www.valionbio.com.

Forward-Looking Statements

This press release may contain “forward-looking

statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained

in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by

the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,”

“expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,”

“predict,” “project,” “target,” “aim,” “should,” “will” “would,”

or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking

statements are based on Valion’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are

difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be

accurate. Forward-looking statements in this press release include, among others, statements regarding: the timing and success of preclinical

and clinical trials and study results, including the AFRRI/NIAID studies described herein; the development and regulatory advancement

of Entolimod under the FDA Animal Rule; the timing and outcome of regulatory or government interactions; the initiation, design,

timing and outcome of investigator-sponsored studies in neutropenia; the development and potential applications of Entolasta; the ability

of the Company to expand the TLR5 platform into oncology supportive care or other indications; and the Company’s ability to obtain

additional capital and the continued listing of the Company’s common stock on the Nasdaq Capital Market. Given these risks and uncertainties,

you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of other risks and uncertainties, and

other important factors, any of which could cause Valion’s actual results to differ from those contained in the forward-looking

statements, see Valion’s filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2025, filed

with the SEC on March 30, 2026, under the heading “Risk Factors”; as well as the Company’s subsequent filings with the

SEC. Forward-looking statements contained in this press release are made as of this date, and Valion undertakes no duty to update such

information except as required by applicable law.

Investor

and Media Contact

Stephen Kilmer

(646) 274-3580

stephen.kilmer@valionbio.com

2

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.3

Cover

Oct. 27, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Oct. 27, 2026

Entity File Number

001-41052

Entity Registrant Name

Valion

Bio, Inc.

Entity Central Index Key

0001787740

Entity Tax Identification Number

81-4016391

Entity Incorporation, State or Country Code

DE

Entity Address, Address Line One

1305 E. Houston Street,

Entity Address, City or Town

San Antonio

Entity Address, State or Province

TX

Entity Address, Postal Zip Code

78205

City Area Code

888

Local Phone Number

276-6888

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value

$0.0001 per share

Trading Symbol

VBIO

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

X

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

na

Period Type:

duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration